[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fDmLVPc10MndFSkfWu7NuqZC94GO4H-JEuBOcobY0meg":8,"$fV2wB1HYTye9Y54TwRJtebUw508jBWqFTgQsPtqTfmVQ":56,"$fmchnxdzv6eNdPlt3PJOjlALV67mtVXHPjDZEeWNBTFI":60},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":55},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":29,"seoKeywords":30,"seoDescription":31,"shelvesTime":32,"version":33,"menus":34,"menuId":36,"type":43,"quality":54,"commentCount":21,"isComment":43},61950,870358,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//KGvUiQyxX7cgFOiNjW883bSOhp4xZi3T.png","罗旭","大连医科大学附属第一医院","肝胆外科","住院医师",53,0,"救命药变毒药？直肠癌肝转移7大用药雷区解析","","https://ystcdn.venuertc.com/venue/AI/03822486-e0ac-460c-8f43-f0c1f757224d.jpg","\u003Cdiv id=\"material_title\" class=\"drugguide-title\">\n  \u003Ch1 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">直肠癌晚期肝转移相关药品使用安全指南\u003C/h1>\n  \u003Cp class=\"drugguide-intro\">说起来，针对直肠癌晚期伴肝转移的药品，大家关注的总是“怎么用才安全、怎么才能减少副作用”。在现代治疗中，针对联合化疗和靶向药物的实际案例，每一步用药细节都决定着疗效和安全。本文将介绍7个实用要点，从服药时间、剂型特点到常见不良反应，帮助你掌握用药关键，让治疗更安心。️\u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"drugguide-section\">\n  \u003Ch2 class=\"drugguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 服用时间和方法\u003C/h2>\n  \u003Cdiv class=\"drugguide-bg\">\n    \u003Cp>\n      在使用化疗方案（如XELOX、FUPEP）与靶向药物（贝伐珠单抗）时，服药时间和方法直接影响疗效与安全。化疗药品如卡培他滨，通常推荐与早餐和晚餐一起口服，以减少胃肠道刺激。贝伐珠单抗这类靶向药物则为静脉注射，需在医院由专业人员操作，绝不自行给药。\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>正确做法：口服药需足量温水送服，注射类药品只接受专业操作。\u003C/li>\n      \u003Cli>需要注意：口服药不可空腹，如有特殊药品剂型说明，应严格按照说明书服用。\u003C/li>\n      \u003Cli>特别提醒：服药时间规律，可以帮助身体维持稳定药物浓度。\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"drugguide-section\">\n  \u003Ch2 class=\"drugguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 剂型特点与服用技巧\u003C/h2>\n  \u003Cdiv class=\"drugguide-bg\">\n    \u003Cp>\n      药品剂型多样，不同类型的药物在服用时有特殊要求。例如：卡培他滨为薄膜衣片，服用时不能咀嚼也不能掰碎，否则影响药效并可能加重副作用。奥沙利铂为静脉点滴，需要专业设备和人员。升红药物（如重组人促红素）则需皮下注射，有专用注射器操作。\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>正确做法：药片需吞服，不能磨碎。注射药品应由护士或医生完成。\u003C/li>\n      \u003Cli>需要注意：如遇吞咽困难，应提出由医师调整剂型。\u003C/li>\n      \u003Cli>特别提醒：瓶装药液如有沉淀、变色，请勿使用。\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"drugguide-section\">\n  \u003Ch2 class=\"drugguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 药物相互作用🌐\u003C/h2>\n  \u003Cdiv class=\"drugguide-bg\">\n    \u003Cp>\n      化疗和靶向药品常与其他药物合用，相互作用风险高。例如：卡培他滨与华法林、苯妥英等药物同用时，可能影响出血风险；贝伐珠单抗与抗高血压药合用，则需密切观测血压变化。升红药物（促红素）如与铁剂同用，一般不会强烈冲突，但如有特殊药物（如某些抗生素、免疫抑制剂）应提前告知医生。\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>正确做法：使用新药前，请主动告知所有正在服用的药物清单。\u003C/li>\n      \u003Cli>需要注意：部分药物需提前数小时服用，不能与化疗药物同服。\u003C/li>\n      \u003Cli>特别提醒：服药期间不要自行加减药品种类。\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"drugguide-section\">\n  \u003Ch2 class=\"drugguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 特殊人群用药调整🧓\u003C/h2>\n  \u003Cdiv class=\"drugguide-bg\">\n    \u003Cp>\n      老年患者、肝肾功能减退者需调整用药方案。例如，71岁女性在贝伐珠单抗治疗中，因为高血压，已降低剂量。肾功能不全患者使用卡培他滨，需要减量。糖尿病患者应用升红药物时需监测血糖和血压变化。孕妇和哺乳期女性一般避免使用多数化疗药品，若必须用药，应由医生严格评估风险后给予最低有效剂量或更安全的替代方案。\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>正确做法：定期检测肝肾功能指标，据指标调整药品剂量。\u003C/li>\n      \u003Cli>需要注意：药品剂量不能自行更改，仅能由专业医生根据检查结果调节。\u003C/li>\n      \u003Cli>特别提醒：有特殊身体状况时，每次新药添加都需重新评估用药安全。\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"drugguide-section\">\n  \u003Ch2 class=\"drugguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 常见不良反应及处理方案⚠️\u003C/h2>\n  \u003Cdiv class=\"drugguide-bg\">\n    \u003Cp>\n      化疗药和靶向药物不良反应种类多。卡培他滨可能导致手足麻木、腹泻、口腔溃疡。贝伐珠单抗常见侧效有高血压、蛋白尿及异常出血。奥沙利铂可能出现末梢神经麻木。升红药物则有轻度头痛、血压波动。临床数据显示，贝伐珠单抗相关高血压发生率约10~20%，卡培他滨胃肠道副作用发生率可超过35%。\u003Cbr>\n      遇到不良反应时，不能随意停药，应及时联系医师，由医师判断是否需要调整药物剂量或更换方案。\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>正确做法：发现副作用后，首先记录症状，尽快告知医师。\u003C/li>\n      \u003Cli>需要注意：出现发热、严重呕吐、皮肤粘膜出血，需紧急就医。\u003C/li>\n      \u003Cli>特别提醒：不可自行选用缓解副作用的非处方药。\u003C/li>\n    \u003C/ul>\n    \u003Cblockquote class=\"drugguide-blockquote\" style=\"border-left: 4px solid rgb(64, 158, 255); background: rgb(240, 247, 255); color: rgb(44, 62, 80); margin: 1em 0px; padding: 12px 20px; border-radius: 4px;\">\n      临床用药案例：有位71岁患者在接受贝伐珠单抗期间，因为高血压调整过剂量，说明特殊不良反应后需及时与医生沟通，不能自行操作。\n    \u003C/blockquote>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"drugguide-section\">\n  \u003Ch2 class=\"drugguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 储存条件与有效期\u003C/h2>\n  \u003Cdiv class=\"drugguide-bg\">\n    \u003Cp>\n      多数化疗药品需低温、避光保存，如奥沙利铂应放在2-8℃冷藏环境；卡培他滨遮光、干燥处常温保存。贝伐珠单抗未开封剂型冷藏，打开须尽快用完。升红药物冷藏保存，严禁冷冻。所有药品的包装上均有有效期提示，开封后如有说明书建议使用时长，应严格遵守。\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>正确做法：存放在儿童无法触及处，每次取药后立即密封。\u003C/li>\n      \u003Cli>需要注意：若发现药品外观异常（变色、沉淀、异味等），禁止使用。\u003C/li>\n      \u003Cli>特别提醒：药品过期必须丢弃，不能继续用于治疗。\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"drugguide-section\">\n  \u003Ch2 class=\"drugguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 漏服及过量应对方法⌛\u003C/h2>\n  \u003Cdiv class=\"drugguide-bg\">\n    \u003Cp>\n      药品漏服和过量服用时，须理性处理。多数口服化疗药漏服一剂，不可双倍补服，应等下一次按正常剂量服用。注射药物如有漏用/多用，应第一时间报告医生，由医生指导后续管理。过量服用可能加重药品毒性，表现为严重的恶心、呕吐、手足损伤或免疫抑制。\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>正确做法：漏服时不加量补服，保持原计划。\u003C/li>\n      \u003Cli>需要注意：如不慎过量，应立即就医，不建议自行处理。\u003C/li>\n      \u003Cli>特别提醒：随身保管并记录每次服药时间，防止遗忘或重复服用。\u003C/li>\n    \u003C/ul>\n    \u003Cblockquote class=\"drugguide-blockquote\" style=\"border-left: 4px solid rgb(64, 158, 255); background: rgb(240, 247, 255); color: rgb(44, 62, 80); margin: 1em 0px; padding: 12px 20px; border-radius: 4px;\">\n      临床用药案例：化疗期间一位患者漏服卡培他滨一剂，按医生建议并未补服，也未发生严重影响，说明理性应对药品漏服至关重要。\n    \u003C/blockquote>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"drugguide-section\">\n  \u003Ch2 class=\"drugguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">附录：药品安全用药关键数据\u003C/h2>\n  \u003Cdiv class=\"drugguide-bg\">\n    \u003Cul>\n      \u003Cli>贝伐珠单抗相关高血压发生率：10~20%（Hurwitz et al., 2004, \u003Cem>J. Clin. Oncol.\u003C/em>）\u003C/li>\n      \u003Cli>卡培他滨胃肠道副作用发生率：35%（Van Cutsem et al., 2001, \u003Cem>J. Clin. Oncol.\u003C/em>）\u003C/li>\n      \u003Cli>化疗药品剂型不可随意掰碎或咀嚼：依据药品说明书规定\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"drugguide-section\">\n  \u003Ch2 class=\"drugguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">小结与安全提醒\u003C/h2>\n  \u003Cdiv class=\"drugguide-bg\">\n    \u003Cp>\n      联合化疗和靶向药物可以提高治疗效果，但每个用药细节都必须重视。建议服药时间规律，剂型操作规范，遇见不良反应及时就医。特殊人群严格调整剂量，储存及登记服药细节，能有效避免药品风险。用药安全无小事，有疑问务必先问专业医生，切勿自行改动用药方案。\u003Cbr>\u003Cbr>最重要的两点是：\u003Cstrong>不良反应及时就医\u003C/strong>与\u003Cstrong>决不可擅自增加或减少剂量\u003C/strong>。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"drugguide-section\">\n  \u003Ch2 class=\"drugguide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">英文文献引用\u003C/h2>\n  \u003Cdiv class=\"drugguide-bg\">\n    \u003Cul>\n      \u003Cli>Hurwitz, H., Fehrenbacher, L., Novotny, W., et al. (2004). Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. \u003Cem>Journal of Clinical Oncology\u003C/em>, 22(1), 117-126. \u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/14665610/\" target=\"_blank\">PubMed\u003C/a>\u003C/li>\n      \u003Cli>Van Cutsem, E., Twelves, C., Cassidy, J., et al. (2001). Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. \u003Cem>Journal of Clinical Oncology\u003C/em>, 19(21), 4097-4106. \u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/11689500/\" target=\"_blank\">PubMed\u003C/a>\u003C/li>\n      \u003Cli>Miwa, M., Ura, M., Nishida, M., Sawada, N., et al. (1998). Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and tumour tissue. \u003Cem>European Journal of Cancer\u003C/em>, 34(8), 1274-1281. \u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/9893642/\" target=\"_blank\">PubMed\u003C/a>\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.drugguide-title {\n  margin-top: 48px;\n  margin-bottom: 32px;\n  padding: 32px 24px;\n  background: linear-gradient(90deg, #e3f2fd 0%, #ffffff 100%);\n  border-radius: 16px;\n}\n.drugguide-intro {\n  font-size: 18px;\n  color: #444;\n  margin-bottom: 8px;\n  line-height: 1.8;\n}\n.drugguide-section {\n  margin-bottom: 32px;\n}\n.drugguide-subtitle {\n  font-size: 24px;\n  font-weight: 700;\n  color: #21548a;\n  margin-bottom: 0;\n  padding: 18px 0 10px 8px;\n  background: linear-gradient(90deg, #e8f5e9 0%, #e3f2fd 40%, #ffffff 100%);\n  border-top-left-radius: 8px;\n  border-top-right-radius: 8px;\n  letter-spacing: 0.05em;\n}\n.drugguide-bg {\n  padding: 24px 20px;\n  background: linear-gradient(90deg, #f7fafc 0%, #fffde9 100%);\n  border-bottom-left-radius: 20px;\n  border-bottom-right-radius: 20px;\n  box-shadow: 0px 6px 18px rgba(33,84,138,0.08);\n}\n.drugguide-bg p {\n  font-size: 18px;\n  color: #222;\n  margin-bottom: 16px;\n  line-height: 1.8;\n}\n.drugguide-bg ul {\n  padding-left: 24px;\n  margin-bottom: 8px;\n}\n.drugguide-bg ul li {\n  font-size: 16px;\n  margin-bottom: 12px;\n  line-height: 1.7;\n  color: #31699e;\n  font-weight: bold;\n  list-style-type: disc;\n}\n.drugguide-blockquote {\n  background: #e3f2fc;\n\u003C/style>","\u003Cdiv id=\"material_title\" class=\"drugguide-title\">\n  \u003Ch1 style=\"color: rgb(44, 62, 80); margin: 1.2em",510,"2025-08-21 18:35:16"," 救命药变毒药？直肠癌肝转移7大用药雷区解析 - 避坑指南  \n"," 直肠癌肝转移用药,抗癌药物副作用,化疗方案选择,靶向治疗禁忌,免疫治疗风险,药物相互作用,肝转移治疗误区  \n"," 本文深度解析直肠癌肝转移患者常见的7大用药雷区，包括化疗剂量误区、靶向药禁忌、免疫治疗风险等，帮助患者避免“救命药变毒药”的悲剧，提供科学用药指导与安全治疗建议。","2025-08-23 19:28:00",2,[35],{"menuId":36,"menuName":37,"parentId":21,"orderNum":33,"path":38,"component":39,"isFrame":40,"isCache":41,"menuType":42,"visible":43,"status":21,"createDept":6,"remark":23,"createTime":44,"children":45,"columnImage":46,"columnLogo":47,"uncheckedLogo":6,"checkedLogo":6,"isHot":43,"isHome":21,"forceLogin":21,"color":48,"seoTitle":49,"seoKeywords":50,"seoDescription":51,"contentNum":6,"promotionalPoster":52,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":53,"routerPath":38,"componentInfo":39},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":57,"success":55},{"pageNo":43,"pageSize":58,"result":59,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":61,"success":55},{"authors":62,"appraiseDimensionScoresVos":63},[],[]]